LEVAMLODIPINE
Dyslipidemia
Stanford UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Dyslipidemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lipitor Johns Hopkins University | Phase 4 | A |
Rosuvastatin Korea University Anam Hospital | Phase 4 | A |
SIMVASTATIN Eli Lilly and Company | Phase 4 | BBB |
Fenofibrate Lewai Sharki Abdulaziz, MSc PhD | Phase 4 | BBB |
ADVICOR COMPONENT NIACIN University of Hawaii | Phase 4 | BBB |
View all 27 →
Same molecule, other indications
LEVAMLODIPINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →